Rapid assay for qualitatively and/or quantitatively determining antibodies against human papillomaviruses of type 16 that are present in body fluid, in which a sample of body fluid is mixed with a reagent which substantially consists of a predefined amount of physiologically-acting liquid and a predefined amount of at least one antigen, the antigen being aggregated and being reactive with regard to antibodies which are present in the body fluid and which are specific against the L1 protein of HPV16 (HPV16L1-specific antibodies) and the liquid acting physiologically on the antigen in order to maintain the reactivity of the antigen with regard to said antibodies, and in which the mixture is subsequently subjected to an analysis, the analysis using: • a conjugate which substantially consists of a predefined amount of at least one molecule and of a substance which brings about a measurable and/or user-perceptible reaction or, in the case of spatial accumulation, yields a measurable and/or user-perceptible change, the at least one molecule being specific against the L1 protein of HPV16 and binding to the antigen when the antigen is still reactive, • a support medium on which or in which the delivered amount of the mixture is flowable in the direction of at least one spatial axis, • a predefined amount of at least one capture molecule which is fixed at a predefined first site or a predefined first region of the support medium and binds to the at least one antigen when the antigen is still reactive, the capture molecule and the molecule of the conjugate being identical to one another such that both form a bond with the antigen, and the antigen still being reactive when HPV16L1-specific antibodies are not present in the sample of body fluid or are below the detection limit of the method. in which a sample of body fluid is mixed with a reagent which substantially consists of a predefined amount of physiologically-acting liquid and a predefined amount of at least one antigen, the antigen being aggregated and being reactive with regard to antibodies which are present in the body fluid and which are specific against the L1 protein of HPV16 (HPV16L1-specific antibodies) and the liquid acting physiologically on the antigen in order to maintain the reactivity of the antigen with regard to said antibodies, and in which the mixture is subsequently subjected to an analysis, the analysis using: • a conjugate which substantially consists of a predefined amount of at least one molecule and of a substance which brings about a measurable and/or user-perceptible reaction or, in the case of spatial accumulation, yields a measurable and/or user-perceptible change, the at least one molecule being specific against the L1 protein of HPV16 and binding to the antigen when the antigen is still reactive, • a support medium on which or in which the delivered amount of the mixture is flowable in the direction of at least one spatial axis, • a predefined amount of at least one capture molecule which is fixed at a predefined first site or a predefined first region of the support medium and binds to the at least one antigen when the antigen is still reactive, the capture molecule and the molecule of the conjugate being identical to one another such that both form a bond with the antigen, and the antigen still being reactive when HPV16L1-specific antibodies are not present in the sample of body fluid or are below the detection limit of the method. • a conjugate which substantially consists of a predefined amount of at least one molecule and of a substance which brings about a measurable and/or user-perceptible reaction or, in the case of spatial accumulation, yields a measurable and/or user-perceptible change, the at least one molecule being specific against the L1 protein of HPV16 and binding to the antigen when the antigen is still reactive, • a support medium on which or in which the delivered amount of the mixture is flowable in the direction of at least one spatial axis, • a predefined amount of at least one capture molecule which is fixed at a predefined first site or a predefined first region of the support medium and binds to the at least one antigen when the antigen is still reactive, the capture molecule and the molecule of the conjugate being identical to one another such that both form a bond with the antigen, and the antigen still being reactive when HPV16L1-specific antibodies are not present in the sample of body fluid or are below the detection limit of the method.